Does Medicare Cover Weight Loss Drugs Like Ozempic? What’s Covered and What’s Not

Despite the explosive popularity of GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound, Medicare still does not cover these drugs when prescribed solely for weight loss or obesity. Federal law continues to ban anti-obesity drug coverage under Part D. However, GLP-1 drugs are covered for specific medical indications — type 2 diabetes, cardiovascular risk reduction, and obstructive sleep apnea — and a CMS bridge program launching in July 2026 may offer limited financial relief. This guide explains exactly what is and is not covered, which conditions qualify, what you will pay, and what options exist if you need a GLP-1 drug for weight management.

What Are GLP-1 Weight Loss Drugs?

GLP-1 receptor agonists are a class of injectable (and in some cases oral) medications originally developed to treat type 2 diabetes. They work by mimicking a natural gut hormone called glucagon-like peptide-1, which signals your brain that you are full, slows stomach emptying, and helps regulate blood sugar levels.

Researchers discovered that GLP-1 drugs also produce significant weight loss — often 15% to 25% of body weight in clinical trials. This dual benefit led pharmaceutical companies to seek FDA approval for these drugs specifically as obesity treatments, separate from their diabetes indications.

Key GLP-1 Medications You Should Know

It is important to understand the distinction between diabetes-indicated drugs (Ozempic, Mounjaro) and weight-management-indicated drugs (Wegovy, Zepbound, Saxenda). Although the active ingredients may be the same, the FDA approval, dosing, and — critically for Medicare — the coverage rules can differ.

What Has — and Has Not — Changed in 2026

A provision in the Social Security Act (Section 1862) explicitly excludes coverage of drugs “used for anorexia, weight loss, or weight gain” from Medicare Part D. That exclusion is still in effect. Despite years of advocacy and the introduction of the Treat and Reduce Obesity Act in multiple congressional sessions, that legislation has not been signed into law as of February 2026.

The Trump Administration’s April 2025 Decision

In April 2025, the Trump administration announced that Medicare and Medicaid would not expand coverage to include anti-obesity medications. This decision effectively halted prior momentum toward broader GLP-1 coverage for weight loss under federal programs. The statutory ban on weight-loss drug coverage under Part D remains unchanged.

What IS Covered Under Part D

Although Medicare does not cover GLP-1 drugs for weight loss or obesity alone, these medications are covered when prescribed for specific FDA-approved medical indications:

• Type 2 diabetes: Ozempic (semaglutide) and Mounjaro (tirzepatide) — Part D has covered these for years
• Cardiovascular risk reduction: Wegovy (semaglutide) for patients with established cardiovascular disease — covered based on its 2024 FDA approval for this indication
• Obstructive sleep apnea: Zepbound (tirzepatide) for adults with obesity and moderate-to-severe OSA — covered based on its FDA-approved indication

The practical result: If you need a GLP-1 drug purely for weight loss, Medicare Part D will not cover it in 2026. However, if you have one of the qualifying medical conditions above, you may be able to get coverage for a GLP-1 medication through your Part D plan.

The CMS Bridge Program (Starting July 2026)

CMS has announced a bridge program beginning in July 2026 that will offer $50 per month toward anti-obesity medications for qualifying Medicare beneficiaries enrolled in Part D. While this does not cover the full cost of GLP-1 drugs (which retail at $900 to $1,300+ per month), it provides modest financial relief. A full pilot program targeting obesity drug coverage is planned for 2027.

A Historical Timeline

Part D Coverage Rules for GLP-1 Drugs

Because the federal ban on anti-obesity drug coverage is still in place, Part D plans can only cover GLP-1 drugs for their approved medical indications — not for weight loss alone. Here is how coverage works for the qualifying conditions:

Covered Indications and Formulary Placement

Part D plans cover GLP-1 drugs for type 2 diabetes (Ozempic, Mounjaro), cardiovascular risk reduction (Wegovy for established CVD), and obstructive sleep apnea (Zepbound for adults with obesity). These drugs are typically placed on Tier 4 (non-preferred specialty) or Tier 5 (specialty) of the formulary. This means higher cost-sharing compared to generic medications, but the Part D out-of-pocket cap still applies.

Prior Authorization

Nearly all Part D plans require prior authorization (PA) before covering GLP-1 medications. Your doctor must submit documentation showing that you meet the clinical criteria for a covered indication. Typical PA requirements include:

• Confirmed diagnosis of type 2 diabetes, established cardiovascular disease, or obstructive sleep apnea
• Clinical notes from a face-to-face evaluation supporting the diagnosis
• Documentation that the drug is being prescribed for the covered medical indication (not weight loss alone)
• A treatment plan that aligns with the FDA-approved use of the medication

Step Therapy

Some plans may implement step therapy requirements, meaning you must try a less expensive treatment first before the plan will approve a more expensive GLP-1 drug. For diabetes, a plan might require trying metformin or other first-line agents before approving Ozempic or Mounjaro.

What Is NOT Covered

Part D plans cannot cover GLP-1 drugs when prescribed solely for weight loss or obesity treatment. If your doctor writes a prescription for Wegovy, Zepbound, or Saxenda with obesity as the only diagnosis, Medicare Part D will deny the claim. The CMS bridge program starting July 2026 offers only $50/month — far less than the $900 to $1,300+ monthly retail cost of these drugs.

What Do GLP-1 Drugs Cost With and Without Medicare Part D?

The retail price of GLP-1 drugs is staggering without insurance. Understanding the difference between covered and uncovered scenarios is critical for budgeting.

Retail Prices Without Coverage

What You Pay With Part D Coverage (for Qualifying Medical Indications)

If your GLP-1 drug is covered under Part D for a qualifying indication (diabetes, CVD risk, or sleep apnea), the most important number to remember is the Part D annual out-of-pocket cap of $2,100 in 2026. Regardless of how expensive your medications are at retail, your total out-of-pocket spending at the pharmacy is capped once you reach this threshold.

Here is how the math typically works for a beneficiary with a covered GLP-1 prescription:

1. Part D Deductible ($615 in 2026): You pay the full cost of your prescriptions until you meet the deductible. With a GLP-1 drug, you may hit this within your first fill.
2. Initial Coverage Phase: After the deductible, you pay your plan’s cost-sharing (typically 25% – 33% for specialty-tier drugs) until your out-of-pocket spending reaches the $2,100 cap.
3. Catastrophic Coverage: Once you hit the $2,100 cap, you pay $0 for the rest of the year.

For beneficiaries with a covered GLP-1 drug, you will likely reach the $2,100 out-of-pocket cap within the first two to three months of the year, after which your remaining prescriptions for the year are covered at no additional cost.

What You Pay WITHOUT Part D Coverage (Weight Loss/Obesity Only)

If you need a GLP-1 drug for weight loss and do not have a qualifying medical indication, you will pay the full retail price — $900 to $1,300+ per month ($10,800 to $15,600+ per year). The CMS bridge program starting July 2026 offers only $50/month, reducing your cost slightly but leaving most of the expense out of pocket.

Compare: Covered vs. Uncovered Scenarios

Who Qualifies for Part D Coverage of GLP-1 Drugs?

Because Medicare does not cover GLP-1 drugs for weight loss alone, eligibility depends on having a qualifying medical condition — not just a high BMI.

Covered Medical Indications

Medicare Part D covers GLP-1 drugs when prescribed for one of these specific conditions:

• Type 2 diabetes: Ozempic (semaglutide) and Mounjaro (tirzepatide) are covered for blood sugar management
• Cardiovascular risk reduction: Wegovy (semaglutide) is covered for patients with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease)
• Obstructive sleep apnea: Zepbound (tirzepatide) is covered for adults with obesity who have moderate-to-severe OSA

What Does NOT Qualify

The following scenarios do not qualify for Part D coverage of GLP-1 drugs, regardless of BMI:

• Obesity or overweight as the sole diagnosis
• General weight management or cosmetic weight loss
• Prediabetes (unless the prescribing doctor can document another covered indication)
• Weight-related conditions such as NAFLD, osteoarthritis, or PCOS — these may support a clinical case, but are not standalone covered indications for GLP-1 drugs under Part D

BMI May Still Matter for Specific Indications

While BMI alone does not qualify you for covered GLP-1 treatment, it plays a role in certain indications. For example, the Zepbound indication for obstructive sleep apnea applies to adults with obesity (generally BMI 30+). Your doctor will determine whether your clinical profile meets the criteria for a covered indication.

Additional Requirements

For any covered indication, most Part D plans and CMS guidelines require:

• A prescription from a licensed healthcare provider (physician, NP, or PA)
• Documentation of the qualifying medical diagnosis with supporting clinical evidence
• Prior authorization submitted by your prescribing provider
• Periodic follow-up visits to monitor progress, side effects, and continued medical necessity

How to Get Covered: Step-by-Step

If you are a Medicare beneficiary and believe you may qualify for Part D coverage of a GLP-1 drug through a covered medical indication, follow these steps:

Step 1: Talk to Your Doctor About Qualifying Conditions

Schedule an appointment with your primary care provider or specialist. Discuss whether you have a qualifying medical condition — type 2 diabetes, established cardiovascular disease, or obstructive sleep apnea. Your doctor will determine if a GLP-1 medication is clinically appropriate for a covered indication.

Step 2: Check Your Part D Formulary

Not all Part D plans cover every GLP-1 drug. Log into your plan’s website or call the member services number to check which GLP-1 medications are on your formulary for your specific indication, what tier they are on, and what prior authorization requirements apply. If your current plan does not cover your prescribed GLP-1 drug, you may want to switch plans during the next enrollment period.

Step 3: Submit Prior Authorization

Your doctor’s office will submit a prior authorization request to your Part D plan. This typically includes clinical documentation of your qualifying diagnosis, supporting lab work or test results, and the rationale for prescribing a GLP-1 medication. PA decisions are usually returned within 24 to 72 hours.

Step 4: Fill Your Prescription

Once approved, take the prescription to your plan’s preferred pharmacy (which may include mail-order options for cost savings). Your pharmacist will apply your Part D coverage, and you will pay only your plan’s cost-sharing amount.

Step 5: Enroll in the Prescription Payment Plan (Optional)

If you want to spread your out-of-pocket costs over the year rather than paying a large amount upfront, contact your Part D plan to enroll in the Medicare Prescription Payment Plan. This option is especially helpful for expensive specialty medications.

Step 6: Follow Up Regularly

Most plans require ongoing documentation of medical necessity. Schedule regular check-ups with your doctor to monitor your condition, blood work, and any side effects. Continued coverage typically requires evidence that the medication is working and remains medically appropriate for the covered indication.

Special Considerations for Diabetes Patients

If you have type 2 diabetes, you are likely already eligible for Part D coverage of Ozempic or Mounjaro under the diabetes indication. If your doctor wants to prescribe Wegovy for cardiovascular risk reduction, you will need documented established cardiovascular disease. If your doctor wants to prescribe Zepbound for sleep apnea, you will need a documented OSA diagnosis. Discuss with your doctor which drug and indication make the most sense for your clinical situation and coverage.

Potential Side Effects to Know About

GLP-1 medications are generally well-tolerated, but they can cause side effects, particularly during the dose-escalation phase:

• Common: Nausea, vomiting, diarrhea, constipation, abdominal pain
• Less common: Gallbladder issues, pancreatitis (rare), injection site reactions
• Serious (rare): Thyroid tumors (boxed warning based on animal studies), severe allergic reactions

Most side effects are mild and diminish over time as your body adjusts. Starting at a low dose and gradually increasing — as prescribed — helps minimize gastrointestinal symptoms.

Frequently Asked Questions